The origins of cancer robustness and evolvability.
暂无分享,去创建一个
Tianhai Tian | Angus Harding | James M Whitacre | T. Tian | A. Harding | J. Whitacre | Sarah Olson | S. Olson | Tianhai Tian
[1] M. Tomasson. Cancer stem cells: A guide for skeptics , 2009, Journal of cellular biochemistry.
[2] Kentaro Yamashita,et al. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. , 2006, Cancer cell.
[3] M. Freeman. Feedback control of intercellular signalling in development , 2000, Nature.
[4] C. Croce,et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[5] W. Stolz,et al. Deficiency of a novel retinoblastoma binding protein 2-homolog is a consistent feature of sporadic human melanoma skin cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[6] R. Day,et al. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. , 1986, Cancer research.
[7] H. Lyng,et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis , 2000, British Journal of Cancer.
[8] Larry S Yaeger,et al. How evolution guides complexity , 2009, HFSP journal.
[9] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[10] H. Kitano. Cancer as a robust system: implications for anticancer therapy , 2004, Nature Reviews Cancer.
[11] P. Glazer,et al. Regulation of DNA repair in hypoxic cancer cells , 2007, Cancer and Metastasis Reviews.
[12] A. Shilatifard,et al. An operational definition of epigenetics. , 2009, Genes & development.
[13] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.
[14] Claude Preudhomme,et al. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. , 2003, Seminars in hematology.
[15] H. Heng,et al. Genome based cell population heterogeneity promotes tumorigenicity: The evolutionary mechanism of cancer , 2009, Journal of cellular physiology.
[16] B. Tran,et al. Survival comparison between glioblastoma multiforme and other incurable cancers , 2010, Journal of Clinical Neuroscience.
[17] R. Hill,et al. The tumor microenvironment and metastatic disease , 2008, Clinical & Experimental Metastasis.
[18] D. Schluter,et al. Adaptation from standing genetic variation. , 2008, Trends in ecology & evolution.
[19] M. Landthaler,et al. Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas , 2005, Modern Pathology.
[20] James M. Whitacre,et al. Degeneracy: a link between evolvability, robustness and complexity in biological systems , 2009, Theoretical Biology and Medical Modelling.
[21] H. Hermeking. p53 enters the microRNA world. , 2007, Cancer cell.
[22] J. Melo,et al. Primitive, Quiescent and Difficult to Kill: The Role of Non-Proliferating Stem Cells in Chronic Myeloid Leukemia , 2006, Cell cycle.
[23] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[24] L. Loeb,et al. Efficiency of carcinogenesis with and without a mutator mutation , 2006, Proceedings of the National Academy of Sciences.
[25] Forest M White,et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.
[26] Farren J. Isaacs,et al. Phenotypic consequences of promoter-mediated transcriptional noise. , 2006, Molecular cell.
[27] R. Gillies,et al. Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.
[28] S. Lindquist,et al. Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi , 2005, Science.
[29] M. West-Eberhard,et al. Developmental plasticity and the origin of species differences , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[30] K. Rejniak,et al. Current trends in mathematical modeling of tumor–microenvironment interactions: a survey of tools and applications , 2010, Experimental biology and medicine.
[31] C. Swanton,et al. Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy , 2009, Cell cycle.
[32] D. Compton,et al. Mechanisms of Chromosomal Instability , 2010, Current Biology.
[33] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[34] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[35] A. Balmain,et al. How many mutations are required for tumorigenesis? implications from human cancer data , 1993 .
[36] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[37] I. Tannock,et al. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] G. Edelman,et al. Degeneracy and complexity in biological systems , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. Tischfield,et al. Somatic recombination redux , 2003, Nature Genetics.
[40] C. Schlichting. Hidden Reaction Norms, Cryptic Genetic Variation, and Evolvability , 2008, Annals of the New York Academy of Sciences.
[41] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[42] C. Roberts,et al. Epigenetics and cancer without genomic instability , 2009, Cell cycle.
[43] S. Leibler,et al. Bacterial Persistence as a Phenotypic Switch , 2004, Science.
[44] John Doyle,et al. Evolutionary dynamics and highly optimized tolerance. , 2005, Journal of theoretical biology.
[45] Z. Herceg,et al. Epigenetic drivers and genetic passengers on the road to cancer. , 2008, Mutation research.
[46] Peter A. Jones,et al. The Epigenomics of Cancer , 2007, Cell.
[47] J. Herman,et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.
[48] M. Pigliucci,et al. Phenotypic plasticity and evolution by genetic assimilation , 2006, Journal of Experimental Biology.
[49] Axel Bender,et al. Networked buffering: a basic mechanism for distributed robustness in complex adaptive systems , 2009, Theoretical Biology and Medical Modelling.
[50] J. Crowe,et al. Preservation of mammalian cells—learning nature's tricks , 2000, Nature Biotechnology.
[51] S. Kauffman. Homeostasis and Differentiation in Random Genetic Control Networks , 1969, Nature.
[52] The age distribution of cancer and a multi-stage theory of carcinogenosis , 2004 .
[53] L. Loeb,et al. Mutational heterogeneity in human cancers: origin and consequences. , 2010, Annual review of pathology.
[54] H. Kitano. Towards a theory of biological robustness , 2007, Molecular systems biology.
[55] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[56] Aleksandar Dakic,et al. Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells , 2007, Science.
[57] P. Armitage,et al. The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis , 1954, British Journal of Cancer.
[58] Frank J. Slack,et al. MicroRNAs and cancer: An overview , 2008, Cell cycle.
[59] J. Buchner,et al. Oncogenic mutations reduce the stability of SRC kinase. , 2004, Journal of molecular biology.
[60] Greg Gibson,et al. Uncovering cryptic genetic variation , 2004, Nature Reviews Genetics.
[61] O. Bogler,et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.
[62] Rafael Sanjuán,et al. Epistasis correlates to genomic complexity , 2006, Proceedings of the National Academy of Sciences.
[63] Kornelia Polyak,et al. Microenvironmental regulation of cancer development. , 2008, Current opinion in genetics & development.
[64] R. Prehn,et al. Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.
[65] L. Loeb,et al. Errors in DNA replication as a basis of malignant changes. , 1974, Cancer research.
[66] P. Nowell,et al. Karyotypic evolution in human malignant melanoma. , 1986, Cancer genetics and cytogenetics.
[67] M. Fukuoka,et al. Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] P. M. Voorhoeve,et al. MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity? , 2010, Biochimica et biophysica acta.
[69] A. Feinberg,et al. The epigenetic progenitor origin of human cancer , 2006, Nature Reviews Genetics.
[70] S. Lindquist,et al. Hsp90 as a capacitor for morphological evolution , 1998, Nature.
[71] Alexander Roesch,et al. A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.
[72] Mark P Little,et al. Cancer models, genomic instability and somatic cellular Darwinian evolution , 2010, Biology Direct.
[73] David E. Housman,et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.
[74] F T Bosman,et al. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma , 2001, International journal of cancer.
[75] J. Lankelma,et al. Doxorubicin gradients in human breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[76] Robert A Gatenby,et al. A theoretical quantitative model for evolution of cancer chemotherapy resistance , 2010, Biology Direct.
[77] K. Polyak,et al. Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.
[78] A. Wagner. Robustness and evolvability: a paradox resolved , 2008, Proceedings of the Royal Society B: Biological Sciences.
[79] M. Huynen,et al. Smoothness within ruggedness: the role of neutrality in adaptation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[80] J. M. Murray,et al. Optimal control for a stochastic model of cancer chemotherapy. , 2000, Mathematical biosciences.
[81] Kornelia Polyak,et al. Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? , 2007, Cell cycle.
[82] Michael Landthaler,et al. RBP2‐H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells , 2007, International journal of cancer.
[83] Zhong Yun,et al. Hypoxic tumor microenvironment and cancer cell differentiation. , 2009, Current molecular medicine.
[84] M. Landthaler,et al. Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells. , 2006, The Journal of investigative dermatology.
[85] S. Lindquist,et al. Heat-shock protein hsp90 governs the activity of pp60v-src kinase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[86] David F. Horrobin,et al. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.
[87] M. Greaves. Cancer stem cells: back to Darwin? , 2010, Seminars in cancer biology.
[88] M. Gassmann,et al. Regulation of the multidrug resistance transporter P‐glycoprotein in multicellular tumor spheroids by hypoxia‐inducible factor‐1 and reactive oxygen species , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[89] Rocio Sotillo,et al. Mitotic chromosomal instability and cancer: mouse modelling of the human disease , 2010, Nature Reviews Cancer.
[90] J. M. Nicholson,et al. On the karyotypic origin and evolution of cancer cells. , 2009, Cancer genetics and cytogenetics.
[91] Doyle,et al. Highly optimized tolerance: robustness and design in complex systems , 2000, Physical review letters.
[92] R. Beckman. Mutator Mutations Enhance Tumorigenic Efficiency across Fitness Landscapes , 2009, PloS one.
[93] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[94] G. Wagner,et al. Mutational robustness can facilitate adaptation , 2010, Nature.
[95] G. Cambray,et al. Synonymous Genes Explore Different Evolutionary Landscapes , 2008, PLoS genetics.
[96] C. Hinshelwood,et al. The stability of various adaptations of Bact. lactis aerogenes (Aerobacter aerogenes) , 1954, Proceedings of the Royal Society of London. Series B - Biological Sciences.
[97] P. Turner,et al. Robustness promotes evolvability of thermotolerance in an RNA virus , 2008, BMC Evolutionary Biology.
[98] C. Croce,et al. A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[99] A. Xu,et al. Receptor tyrosine kinase coactivation networks in cancer. , 2010, Cancer research.
[100] A. Wagner. Distributed robustness versus redundancy as causes of mutational robustness. , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.
[101] S. Morrison,et al. Efficient tumor formation by single human melanoma cells , 2008, Nature.
[102] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[103] John Doyle,et al. Complexity and robustness , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[104] G. Parmigiani,et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers , 2008, Proceedings of the National Academy of Sciences.
[105] K. Kinzler,et al. Epitope landscape in breast and colorectal cancer. , 2008, Cancer research.
[106] P. Vaupel,et al. Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.
[107] J. Jonkers,et al. Modeling therapy resistance in genetically engineered mouse cancer models. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[108] Jesse J Salk,et al. Optimization of DNA polymerase mutation rates during bacterial evolution , 2009, Proceedings of the National Academy of Sciences.
[109] D. Alberts,et al. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. , 1986, Cancer research.
[110] Andreas Wagner,et al. Robustness Can Evolve Gradually in Complex Regulatory Gene Networks with Varying Topology , 2007, PLoS Comput. Biol..
[111] R. Milo,et al. Dynamic Proteomics of Individual Cancer Cells in Response to a Drug , 2008, Science.
[112] Carissa A. Sanchez,et al. Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.
[113] Izhak Haviv,et al. Co-evolution of tumor cells and their microenvironment. , 2009, Trends in genetics : TIG.
[114] F. Arnold,et al. Protein stability promotes evolvability. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[115] R. Jaenisch,et al. Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.
[116] J H Goldie,et al. A stochastic model for the origin and treatment of tumors containing drug-resistant cells. , 1986, Bulletin of mathematical biology.
[117] S. Kauffman,et al. Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. , 2009, Seminars in cell & developmental biology.
[118] Lynn Doucette-Stamm,et al. A C . elegans genome-scale microRNA network contains composite feedback motifs with high flux capacity , 2008 .
[119] J. Troge,et al. Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.
[120] Axel Bender,et al. Degeneracy: a design principle for achieving robustness and evolvability. , 2009, Journal of theoretical biology.
[121] R. Stephens,et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.
[122] John C Reed,et al. Heat-shock proteins as regulators of apoptosis , 2003, Oncogene.
[123] M. Fraga,et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.
[124] A. van Oudenaarden,et al. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. , 2007, Molecular cell.
[125] J. Stelling,et al. Robustness of Cellular Functions , 2004, Cell.
[126] Thomas J. Hardcastle,et al. Chromosomal instability determines taxane response , 2009, Proceedings of the National Academy of Sciences.
[127] C. Maley,et al. Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .
[128] R. Weinberg,et al. Species- and cell type-specific requirements for cellular transformation. , 2004, Cancer cell.
[129] C. Croce,et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[130] Franziska Michor,et al. Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..
[131] Hannah H. Chang,et al. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells , 2008, Nature.
[132] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[133] Manel Esteller,et al. Mutator pathways unleashed by epigenetic silencing in human cancer. , 2007, Mutagenesis.
[134] A. Knudson. Hereditary cancer: Two hits revisited , 2005, Journal of Cancer Research and Clinical Oncology.
[135] Jarle Breivik,et al. The evolutionary origin of genetic instability in cancer development. , 2005, Seminars in cancer biology.
[136] D. Elder,et al. Familial cutaneous melanoma and two‐mutational‐event modeling , 1993, Cancer.
[137] S. Kauffman. Metabolic stability and epigenesis in randomly constructed genetic nets. , 1969, Journal of theoretical biology.
[138] Nicholas D. Socci,et al. Mad2-induced chromosome instability leads to lung tumor relapse after oncogene withdrawal , 2010, Nature.
[139] Edward R Sumner,et al. Glutathione and Gts1p drive beneficial variability in the cadmium resistances of individual yeast cells , 2007, Molecular microbiology.
[140] R. Stephens,et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.
[141] G. Wagner,et al. EVOLUTION AND DETECTION OF GENETIC ROBUSTNESS , 2003 .
[142] S. Sone,et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. , 2005, Oncology research.
[143] Dan S. Tawfik,et al. Chaperonin overexpression promotes genetic variation and enzyme evolution , 2009, Nature.
[144] Darryl Shibata,et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis , 1993, Nature.
[145] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[146] Martin A Nowak,et al. Evolutionary dynamics of escape from biomedical intervention , 2003, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[147] R. Morimoto,et al. Molecular chaperones and the stress of oncogenesis , 2004, Oncogene.
[148] M. Greaves,et al. Phenotypic heterogeneity and cellular origins of T cell malignancies. , 1981, Leukemia research.
[149] P. Vaupel,et al. Tumor hypoxia and malignant progression. , 2009, Methods in enzymology.
[150] T. Richmond,et al. Crystal structure of the nucleosome core particle at 2.8 Å resolution , 1997, Nature.
[151] Bryan C. Daniels,et al. Sloppiness, robustness, and evolvability in systems biology. , 2008, Current opinion in biotechnology.
[152] S. Lowe,et al. A microRNA polycistron as a potential human oncogene , 2005, Nature.
[153] R. Jaenisch,et al. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice , 2008, Oncogene.
[154] A. Knudson,et al. Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.
[155] E. Bongcam-Rudloff,et al. Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cells in vitro. , 1997, Cancer research.
[156] Alexei Kurakin,et al. Scale-free Flow of Life: On the Biology, Economics, and Physics of the Cell , 2009 .
[157] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[158] Peter A. Jones,et al. Epigenetics in cancer. , 2010, Carcinogenesis.
[159] N. Copeland,et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.
[160] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[161] Hannah H. Chang,et al. Non-genetic heterogeneity — a mutation-independent driving force for the somatic evolution of tumours , 2009, Nature Reviews Genetics.
[162] Allan H Friedman,et al. Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[163] M. Delbrück,et al. Mutations of Bacteria from Virus Sensitivity to Virus Resistance. , 1943, Genetics.
[164] Sam W. Lee,et al. Clonal selection in malignant transformation of human fibroblasts transduced with defined cellular oncogenes. , 2008, Cancer research.
[165] M. Landthaler,et al. Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma , 2005, Modern Pathology.
[166] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.